U.S. generic sulfamethoxazole/trimethoprim products can involve several different organizations: the applicant for an approved drug, the company that physically manufactures it, the labeler that submits an NDC listing, and a repackager or relabeler. A company name on a pharmacy bottle therefore does not necessarily identify the factory that made the medicine.
To understand a specific generic TMP-SMX tablet or oral suspension, begin with its complete two-ingredient name, strength, route, NDC and official label record. FDA’s NDC Directory is based on information submitted by labelers; an NDC number is not by itself evidence of FDA approval, a guarantee of present inventory or a certificate of manufacturing quality.
This is a verification methodology rather than a ranking of manufacturers or a promise that any named firm currently supplies local pharmacies. The generic Bactrim guide explains therapeutic equivalence at the product level; the liquid product guide covers a distinct formulation.
The manufacturer is involved in making the dosage form. A labeler is the entity responsible for submitted listing information and may be the producer or a different firm distributing a product under its name. A repackager can transfer finished medicine to new packaging. Avoid calling all three the “maker” without documentary support.
A National Drug Code identifies a listed drug product and package in the FDA directory, but it does not show which neighborhood pharmacy has units on hand. NDC data can change when products are marketed or discontinued, and the FDA explicitly warns that a listing is not proof of approved status or reimbursement eligibility.
The Orange Book can help identify approved drug applications and therapeutic-equivalence information. Match the active ingredients, strength, dosage form, route and company/product details. Do not conclude that two products are equivalent simply because their NDC product descriptions share a partial generic name.
A manufacturer name is only one possible entry in the record of a generic drug. The table separates an FDA application holder, a firm making a product, an NDC labeler and a repackager because each can be a different organization. Before drawing conclusions about a specific package, confirm the two active ingredients, dosage form and marketed presentation; FDA listing data alone neither certify approval nor verify inventory.
| Record field | Useful interpretation | Wrong conclusion to avoid |
|---|---|---|
| Proprietary / nonproprietary name | Which TMP-SMX product is described | Name alone confirms equivalent formulation |
| Ingredient strength | 400/80 mg, 800/160 mg or liquid concentration | Interchangeable units across forms |
| Labeler | Company responsible for listing | Necessarily the physical factory |
| Packager / relabeler | Company handling distribution packaging | Original drug manufacturer |
| NDC | Identifies listed product/package | FDA approval or local availability |
| Application / approval | Regulatory product context | Proof of current pharmacy shelf inventory |
A company associated with an 800/160 mg tablet does not automatically supply 200/40 mg per 5 mL oral suspension. Generic manufacturers can market only selected dosage forms or strengths. Compare the exact form and strength before drawing conclusions from a brand or supplier name.
Pharmacies may switch between appropriately approved generic suppliers for procurement reasons. The correct check is active ingredients, authorized dosage form, strength, therapeutic-equivalence status and the prescriber’s order. Supplier nationality or packaging appearance is not a reliable quality ranking.
Without consistent, validated comparative evidence across manufacturers, ranking companies by effectiveness would be misleading. Regulatory approval, current safety communications, product identity and the pharmacist’s dispensing obligations provide a more reliable framework than unsupported top-ten lists or anonymous retail testimonials.
Ask which exact NDC will be dispensed, what company the official label identifies, whether the product is FDA-approved and suitable for the order, and whether the pharmacy has it. If the item changes, request identification and counseling. The tablet product directory explains the two standard tablet strength families.
Not necessarily. The printed company may be a labeler, distributor, relabeler or repackager.
A National Drug Code used to identify a listed U.S. drug product and package.
No. FDA explicitly states that an NDC assignment does not establish approval.
No. Real-time inventory must be checked with the pharmacy.
No. Verify the specific dosage form and strength for the product.
Use FDA-approved-drug resources, official labeling and pharmacist verification for the exact product.
A universal ranking is not supported by reliable head-to-head evidence; focus on approved product identity and dispensing checks.